Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Page 1
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Lancet. 2023 Jul 22;402(10398):291-303. doi: 10.1016/S0140-6736(23)01055-3. Epub 2023 Jun 4.
Lancet. 2023.
PMID: 37285865
Clinical Trial.
Combining next-generation hormonal therapy with PARP inhibition in metastatic castration-resistant prostate cancer.
Abida W, Attard G.
Abida W, et al.
Lancet. 2023 Jul 22;402(10398):266-267. doi: 10.1016/S0140-6736(23)01123-6. Epub 2023 Jun 4.
Lancet. 2023.
PMID: 37285866
No abstract available.
Item in Clipboard
Cite
Cite